Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS)

Gynecological Endocrinology

Volumn 30, Issue 4, 2014, Pages 260-265

  Rutkowska, Aleksandra ^a   Rachoń, Dominik ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bisphenol A; Endocrine disruptors; Hyperandrogenism; Hyperinsulinemia; Polycystic ovary syndrome

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; DNA; ESTROGEN RECEPTOR; BENZHYDRYL DERIVATIVE; ENDOCRINE DISRUPTOR; PHENOL DERIVATIVE;

DNA MODIFICATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMICALLY INDUCED; FEMALE; PATHOLOGY; PREGNANCY; TOXICITY;

ANIMALS; BENZHYDRYL COMPOUNDS; ENDOCRINE DISRUPTORS; FEMALE; HUMANS; PHENOLS; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 84897900865     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.871517     Document Type: Review

References (93)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89: 2745-9.
2. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293: 355-9.
3. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85: 89-94.
4. Vutyavanich T, Khaniyao V, Wongtra-Ngan S, et al. Clinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women. J Obstet Gynaecol Res 2007;33: 677-80.
5. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12: 673-83.
6. Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Med Clin North Am 2008;92: 1163-92, xi.
7. Agrawal R, Sharma S, Bekir J, et al. Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Fertil Steril 2004;82: 1352-7.
8. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59: 141-54.
9. Rachoń D, Teede H. Ovarian function and obesity - interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol 2010;316: 172-9.
10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84: 165-9.
11. Strowitzki T, Halser B, Demant T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome. Gynecol Endocrinol 2002;16: 45-51.
12. Valkenburg O, Steegers-Theunissen RP, Smedts HP, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93: 470-6.
13. Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28: 439-58, viii.
14. Legro RS, Urbanek M, Kunselman AR, et al. Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril 2002;78: 51-7.
15. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93: 1276-84.
16. Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod 2011;26: 202-13.
17. Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91: 1357-63.
18. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993;101: 378-84.
19. Cobellis L, Latini G, De Felice C, et al. High plasma concentrations of di-(2-ethylhexyl)-phthalate in women with endometriosis. Hum Reprod 2003;18: 1512-15.
20. Yokota H, Iwano H, Endo M, et al. Glucuronidation of the environmental oestrogen bisphenol A by an isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Biochem J 1999;340: 405-9.
21. Vandenberg LN, Hauser R, Marcus M, et al. Human exposure to bisphenol A (BPA). Reprod Toxicol 2007;24: 139-77.
22. Ikezuki Y, Tsutsumi O, Takai Y, et al. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 2002;17: 2839-41.
23. Vandenberg LN, Chahoud I, Heindel JJ, et al. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Ciencia Saude Coletiva 2012;17: 407-34.
24. Erler C, Novak J. Bisphenol a exposure: human risk and health policy. J Pediatr Nurs 2010;25: 400-7.
25. Vogel SA. The politics of plastics: the making and unmaking of bisphenol a "safety". Am J Public Health 2009;99:S559-66.
26. Ben-Jonathan N, Steinmetz R. Xenoestrogens: the emerging story of bisphenol a. Trends Endocrinol Metab 1998;9: 124-8.
27. Gould JC, Leonard LS, Maness SC, et al. Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. Mol Cell Endocrinol 1998;142: 203-14.
28. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139: 4252-63.
29. Watson CS, Bulayeva NN, Wozniak AL, Alyea RA. Xenoestrogens are potent activators of nongenomic estrogenic responses. Steroids 2007;72: 124-34.
30. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006;102: 175-9.
31. Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 2005;70: 364-71.
32. Takeda Y, Liu X, Sumiyoshi M, et al. Placenta expressing the greatest quantity of bisphenol A receptor ERR{gamma} among the human reproductive tissues: predominant expression of type-1 ERRgamma isoform. J Biochem 2009;146: 113-22.
33. Arase S, Ishii K, Igarashi K, et al. Endocrine disrupter bisphenol A increases in situ estrogen production in the mouse urogenital sinus. Biol Reprod 2011;84: 734-42.
34. Kruger T, Long M, Bonefeld-Jorgensen EC. Plastic components affect the activation of the aryl hydrocarbon and the androgen receptor. Toxicology 2008;246: 112-23.
35. Bonefeld-Jorgensen EC, Long M, Hofmeister MV, Vinggaard AM. Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review. Environ Health Perspect 2007;115: 69-76.
36. Chapin RE, Adams J, Boekelheide K, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol A. Birth Defects Res B Dev Reprod Toxicol 2008;83: 157-395.
37. Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 2006;147: S56-69.
38. Kim YH, Kim CS, Park S, et al. Gender differences in the levels of bisphenol A metabolites in urine. Biochem Biophys Res Commun 2003;312: 441-8.
39. Fernandez MF, Arrebola JP, Taoufiki J, et al. Bisphenol-A and chlorinated derivatives in adipose tissue of women. Reprod Toxicol 2007;24: 259-64.
40. Takeuchi T, Tsutsumi O, Ikezuki Y, et al. Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocrine J 2006; 53: 485-91.
41. Matsushima A, Teramoto T, Okada H, et al. ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner. Biochem Biophys Res Commun 2008;373: 408-13.
42. Newbold RR, Jefferson WN, Padilla-Banks E. Long-term adverse effects of neonatal exposure to bisphenol A on the murine female reproductive tract. Reprod Toxicol 2007;24: 253-8.
43. Markey CM, Coombs MA, Sonnenschein C, Soto AM. Mammalian development in a changing environment: exposure to endocrine disruptors reveals the developmental plasticity of steroid-hormone target organs. Evol Develop 2003;5: 67-75.
44. Erhlich S, Williams PL, Missmer SA, et al. Urinary bisphenol A concentrations and implantation failure among women undergoing in vitro fertilization. Environ Health Perspect 2012;120: 978-83.
45. Skinner MK, Haque CG, Nilsson E, et al. Environmentally induced transgenerational epigenetic reprogramming of primordial germ cells and the subsequent germ line. PLoS One 2013;8:e66318.
46. Machtinger R, Combelles CM, Missmer SA, et al. Bisphenol-A and human oocyte maturation in vitro. Hum Reprod 2013;28: 2735-45.
47. Barontini M, Garcia-Rudaz MC, Veldhuis JD. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Medical Res 2001;32: 544-52.
48. Fernandez M, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect 2010;118: 1217-22.
49. Zhou W, Liu J, Liao L, et al. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol 2008;283: 12-18.
50. Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab 2011;96:E480-4.
51. Nilsson E, Larsen G, Manikkam M, et al. Environmentally induced epigenetic transgenerational inheritance of ovarian disease. PLos One 2012;7:e36129.
52. Dechaud H, Ravard C, Claustrat F, et al. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1999; 64: 328-34.
53. Lord J, Thomas R, Fox B, et al. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113: 1203-9.
54. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reprod Update 2010;16: 347-63.
55. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18: 774-800.
56. Wang T, Li M, Chen B, et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab 2012;97:E223-7.
57. Galloway T, Cipelli R, Guralnik J, et al. Daily bisphenol A excretion and associations with sex hormone concentrations: results from the InCHIANTI adult population study. Environ Health Perspect 2010; 118: 1603-8.
58. Zhao HY, Bi YF, Ma LY, et al. The effects of bisphenol A (BPA) exposure on fat mass and serum leptin concentrations have no impact on bone mineral densities in non-obese premenopausal women. Clin Biochem 2012;45: 1602-6.
59. Phrakonkham P, Viengchareun S, Belloir C, et al. Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. J Steroid Biochem Molec Biol 2008;110: 95-103.
60. Somm E, Schwitzgebel VM, Toulotte A, et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect 2009;117: 1549-55.
61. Masuno H, Iwanami J, Kidani T, et al. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci 2005;84: 319-27.
62. Wada K, Sakamoto H, Nishikawa K, et al. Life style-related diseases of the digestive system: endocrine disruptors stimulate lipid accumulation in target cells related to metabolic syndrome. J Pharmacol Sci 2007;105: 133-7.
63. Alonso-Magdalena P, Morimoto S, Ripoll C, et al. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect 2006;114: 106-12.
64. Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008;300: 1303-10.
65. Tarantino G, Valentino R, Di Somma C, et al. Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol 2013;78: 447-53.
66. Jayashree S, Indumathi D, Akilavalli N, et al. Effect of bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino rat. Environ Toxicol Pharmacol 2013;35: 300-10.
67. Alonso-Magdalena P, Ropero AB, Carrera MP, et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS One 2008;3:e2069.
68. Quesada I, Fuentes E, Viso-Leon MC, et al. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17betaestradiol rapidly activate transcription factor CREB. FASEB J 2002; 16: 1671-3.
69. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Develop 2003;17: 1575-80.
70. Alonso-Magdalena P, Vieira E, Soriano S, et al. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect 2010;118: 1243-50.
71. Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect 2005; 113: 969-77.
72. Gonzalez F, Thusu K, Abdel-Rahman E, et al. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48: 437-41.
73. Kaya C, Akgul E, Pabuccu R. C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. Fertil Steril 2010;94: 230-5.
74. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95:1048-58, e1041-2.
75. Kaya C, Pabuccu R, Berker B, Satiroglu H. Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertil Steril 2010;93: 1200-7.
76. Gonzalez F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab: Clin Experiment 2009;58: 954-62.
77. Ben-Jonathan N, Hugo ER, Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: implications for the metabolic syndrome. Mol Cell Endocrinol 2009;304: 49-54.
78. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocrine Metabolic Disord 2007;8: 127-41.
79. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005;11: 631-43.
80. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84: 4006-11.
81. Fernandez M, Bianchi M, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. Environ Health Perspect 2009;117: 757-62.
82. Susiarjo M, Hassold TJ, Freeman E, Hunt PA. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. PLoS Genet 2007; 3:e5.
83. Rubin BS, Lenkowski JR, Schaeberle CM, et al. Evidence of altered brain sexual differentiation in mice exposed perinatally to low, environmentally relevant levels of bisphenol A. Endocrinology 2006;147: 3681-91.
84. Palanza PL, Howdeshell KL, Parmigiani S, vom Saal FS. Exposure to a low dose of bisphenol A during fetal life or in adulthood alters maternal behavior in mice. Environ Health Perspect 2002;110: 415-22.
85. Kawai K, Nozaki T, Nishikata H, et al. Aggressive behavior and serum testosterone concentration during the maturation process of male mice: the effects of fetal exposure to bisphenol A. Environ Health Perspect 2003;111: 175-8.
86. Vandenberg LN, Chahoud I, Heindel JJ, et al. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ Health Perspect 2010;118: 1055-70.
87. Matsumoto J, Yokota H, Yuasa A. Developmental increases in rat hepatic microsomal UDP-glucuronosyltransferase activities toward xenoestrogens and decreases during pregnancy. Environ Health Perspect 2002;110: 193-6.
88. Taylor JA, Welshons WV, Vom Saal FS. No effect of route of exposure (oral; subcutaneous injection) on plasma bisphenol A throughout 24h after administration in neonatal female mice. Reprod Toxicol 2008;25: 169-76.
89. Mannan MA, O'Shaughnessy PJ. Steroidogenesis during postnatal development in the mouse ovary. J Endocrinol 1991;130: 101-6.
90. Vandenberg LN, Maffini MV, Wadia PR, et al. Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development of the fetal mouse mammary gland. Endocrinology 2007;148: 116-27.
91. Yaoi T, Itoh K, Nakamura K, et al. Genome-wide analysis of epigenomic alterations in fetal mouse forebrain after exposure to low doses of bisphenol A. Biochem Biophys Res Commun 2008;376: 563-7.
92. Bromer JG, Zhou Y, Taylor MB, et al. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J 2010;24: 2273-80.
93. Qu F, Wang FF, Yin R, et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med (Berl) 2012;90: 911-23.